Structural highlights
Function
A0A3R6V2N2_9CLOT
Publication Abstract from PubMed
Anti-CRISPR (Acr) proteins are naturally evolved inhibitors that precisely target and suppress CRISPR-Cas systems, representing a sophisticated molecular arms race between bacteriophages and their bacterial hosts. While Class 1 systems dominate among sequenced prokaryotic genomes, Class 2 systems remain primary sources of editing tools. Here, we report the structural and mechanistic characterization of AcrIIA11, an anti-CRISPR protein that simultaneously inhibits Streptococcus pyogenes (SpyCas9) and Staphylococcus aureus Cas9 (SauCas9). The 3.2 A crystal structure reveals a compact alpha/beta fold with distinct electropositive clefts implicated in DNA binding. While DALI analysis identified structural homology to transcriptional regulators and the RecA inhibitor PsiB (RMSD 3.3 A), functional studies established that AcrIIA11 forms stable ternary complexes with both Cas9 orthologs and sgRNA. Biochemical assays demonstrated stronger inhibition of SauCas9 compared to SpyCas9, with EMSA revealing a critical dichotomy: AcrIIA11 maintains SauCas9-sgRNA binding to specific target DNA while completely blocking cleavage activity. Computational docking localizes AcrIIA11 at the HNH-RuvC interface without obstructing DNA-binding channels in SauCas9, suggesting allosteric inhibition through HNH domain displacement. This work establishes AcrIIA11 as a dual-purpose Cas9 inhibitor that preserves target recognition while inactivating nuclease function-a mechanism with potential applications in precision CRISPR control.
Crystal structure and inhibition mechanism of AcrIIA11.,Cao X, Gao Z, Yin P, Wang H, Yang L Biochem Biophys Res Commun. 2025 Jul 30;772:152073. doi: , 10.1016/j.bbrc.2025.152073. Epub 2025 May 22. PMID:40414010[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Cao X, Gao Z, Yin P, Wang H, Yang L. Crystal structure and inhibition mechanism of AcrIIA11. Biochem Biophys Res Commun. 2025 Jul 30;772:152073. PMID:40414010 doi:10.1016/j.bbrc.2025.152073